Investigational drug · Phase 2
KN713
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC).
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "KN713"
First trial start
2025
Dec 16, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KN713", any sponsor or status.
Conditions studied
As listed on its trial records.
- Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Approved drugs for the same conditions: Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "KN713" as an intervention, largest first.
New Cancer Cure-Bio Co.,Ltd.Industry
NCT07114861 · 30 participants (planned) · Start Dec 16, 2025 · Primary completion Sep 22, 2028
Drug: Study drug: KN510 120mg/day + KN713 90mg/day, Combination Chemotherapy: mFOLFIRINOX; Study drug: KN510 120mg/day + KN713 120mg/day, Combination Chemotherapy: mFOLFIRINOX · For: Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Sites: Goyang-si, South Korea
New Cancer Cure-Bio Co.,Ltd.Industry
NCT06012708 · 12 participants · Start Sep 11, 2023 · Primary completion Nov 5, 2024
Drug: KN510 60mg/day + KN713 60mg/day; KN510 120mg/day + KN713 60mg/day and 2 more · For: Advanced Solid Tumors
Sites: Goyang-si, South Korea
Newest research
PubMed records naming it or its code names, newest first.
- Phase 1 Study of Safety and PK With A Combination of Omeprazole and Trimetazidine for Fatty Acid Oxidation Inhibition in Patients With Advanced Solid Tumors.
Choi W, Chun JW, Sim SH, et al. · Clin Transl Sci 2026
- Inhibiting Fatty Acid Oxidation Reverses Autophagy-Mediated Acquired Chemotherapy Resistance in Pancreatic Ductal Adenocarcinoma.
Woo SM, Kang JH, Choi W, et al. · Cancer Res 2026
- Inhibiting Fatty Acid Oxidation Suppresses Acquired Resistance to Standard Chemotherapy in Melanoma.
Choi W, Ham W, Park JH, et al. · Int J Mol Sci 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.